AbbVie: An Ideal Pick During Uncertain Times
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: NASDAQ.COM
- Stable Business Model: AbbVie has increased its dividend for 53 consecutive years since its founding in 1888, demonstrating strong business stability that attracts shareholders seeking safe investments, especially in uncertain market conditions.
- Strong Growth Prospects: AbbVie's revenue jumped 12.4% year-over-year in Q1 2026, while its competitor Hormel Foods only saw a 2% increase, showcasing its competitive edge and future growth potential in the pharmaceutical industry.
- Attractive Dividend Yield: With a dividend yield exceeding 3.2%, AbbVie significantly outperforms many other Dividend Kings, such as Walmart's 0.74%, making it more appealing to income-focused investors.
- Valuation Advantage: AbbVie's forward price-to-earnings ratio of 14.7 is below the healthcare sector's 16.8, indicating attractive investment value in the current market, particularly amid increasing economic uncertainty.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 218.630
Low
223.00
Averages
252.00
High
289.00
Current: 218.630
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VENCLYXTO Receives Expanded EU Indication Approval
- New Indication Approval: AbbVie announced that the European Commission has approved an expanded indication for VENCLYXTO® (venetoclax) in combination with acalabrutinib (with or without obinutuzumab) and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), enhancing the company's competitive position in the hematologic cancer market.
- Clinical Trial Support: The combination of VENCLYXTO with acalabrutinib is supported by data from the AMPLIFY trial, while the combination with ibrutinib is backed by the GLOW and CAPTIVATE trials, demonstrating significant efficacy and safety advantages that further solidify AbbVie's leadership in oncology treatment.
- Diverse Treatment Options: The newly approved fixed-duration, chemotherapy-free VENCLYXTO combination regimens provide patients with additional treatment options that may offer potential treatment-free intervals, helping patients better manage their disease and improve quality of life, reflecting AbbVie's keen insight and responsiveness to patient needs.
- Market Expansion Potential: This expanded indication approval applies to all EU member states, as well as Iceland, Norway, and Liechtenstein, marking further expansion for AbbVie in the global market, expected to drive sales growth in Europe and enhance its share in the global hematologic cancer treatment market.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AbbVie Receives EU Approval for Expanded VENCLYXTO Indications
- Indication Expansion: AbbVie announced that the European Commission has approved an expanded label for VENCLYXTO to include its use in combination with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia patients, enhancing its market competitiveness.
- Clinical Trial Support: The efficacy of VENCLYXTO in combination with acalabrutinib is supported by data from the Phase 3 AMPLIFY trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to chemoimmunotherapy, showcasing significant clinical advantages.
- Survival Improvement: The combination of VENCLYXTO with ibrutinib is also backed by data from the Phase 3 GLOW and Phase 2 CAPTIVATE trials, which indicated clinically meaningful improvements in progression-free survival and overall survival at a 64-month follow-up.
- Market Impact: This authorization extends to all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive ABBV's sales growth in the European market and further solidify its leadership position in blood cancer treatment.
See More
European Commission Approves Expanded Indication for VENCLYXTO
- Indication Expansion: The European Commission has approved the use of VENCLYXTO in combination with acalabrutinib (with or without obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), significantly broadening its application in first-line treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib was shown to be superior to chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, thus providing patients with a more effective treatment option.
- Patient Benefits: The introduction of these new combination regimens not only offers chemotherapy-free fixed-duration options but also has the potential for treatment-free intervals, significantly improving patients' quality of life and reducing treatment burdens.
- Market Impact: This approval allows VENCLYXTO to be available across all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive AbbVie's sales growth in the European market and further solidify its leadership in the blood cancer treatment sector.
See More
AbbVie Expands VENCLYXTO Indication for CLL Treatment
- Indication Expansion: The European Commission has authorized the use of VENCLYXTO in combination with acalabrutinib (with optional obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), further solidifying AbbVie's leadership in hematologic cancer treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib demonstrated superior efficacy over chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, providing patients with a more effective treatment option.
- Patient Benefits: The new therapy's fixed-duration and chemotherapy-free nature offers the potential for treatment-free intervals, significantly improving patients' quality of life and meeting the evolving needs of patients and healthcare providers for flexible treatment options.
- Market Potential: With VENCLYXTO approved in over 80 countries, AbbVie enhances its competitive edge in the global market through this indication expansion, which is expected to drive future revenue growth for the company.
See More
Analysis of High-Yield Dividend ETF Investments
- Overview of High-Yield ETFs: The Vanguard High Dividend Yield ETF (VYM) includes 608 stocks with a current dividend yield of 2.24%, and while it has underperformed the S&P 500 over the past five years, it has outperformed it in 2026, indicating its potential for providing steady income during volatile periods.
- Portfolio Diversification: VYM's largest sector is financials (20.2%), followed by technology (14.8%) and industrials (14.2%), allowing investors to diversify risks across different economic sectors and reduce reliance on a single industry.
- Schwab Dividend ETF Performance: The Schwab U.S. Dividend Equity ETF (SCHD) holds 103 stocks with a dividend yield of 3.29%, and although its long-term performance has lagged behind VYM and the S&P 500, it has shown strong performance in 2026 with a year-to-date total return of about 17.8%.
- Considerations for ETF Selection: When choosing between VYM and SCHD, investors should consider diversification and safety, as VYM offers greater diversification with 608 stocks, while SCHD is more attractive in terms of dividend yield, making it suitable for those seeking stable income.
See More
VENCLYXTO Receives Expanded EU Indication Approval
- New Indication Approval: AbbVie announced that the European Commission has approved an expanded indication for VENCLYXTO® (venetoclax) in combination with acalabrutinib (with or without obinutuzumab) and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), enhancing the company's competitive position in the hematologic cancer market.
- Clinical Trial Support: The combination of VENCLYXTO with acalabrutinib is supported by data from the AMPLIFY trial, while the combination with ibrutinib is backed by the GLOW and CAPTIVATE trials, demonstrating significant efficacy and safety advantages that further solidify AbbVie's leadership in oncology treatment.
- Diverse Treatment Options: The newly approved fixed-duration, chemotherapy-free VENCLYXTO combination regimens provide patients with additional treatment options that may offer potential treatment-free intervals, helping patients better manage their disease and improve quality of life, reflecting AbbVie's keen insight and responsiveness to patient needs.
- Market Expansion Potential: This expanded indication approval applies to all EU member states, as well as Iceland, Norway, and Liechtenstein, marking further expansion for AbbVie in the global market, expected to drive sales growth in Europe and enhance its share in the global hematologic cancer treatment market.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AbbVie Receives EU Approval for Expanded VENCLYXTO Indications
- Indication Expansion: AbbVie announced that the European Commission has approved an expanded label for VENCLYXTO to include its use in combination with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia patients, enhancing its market competitiveness.
- Clinical Trial Support: The efficacy of VENCLYXTO in combination with acalabrutinib is supported by data from the Phase 3 AMPLIFY trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to chemoimmunotherapy, showcasing significant clinical advantages.
- Survival Improvement: The combination of VENCLYXTO with ibrutinib is also backed by data from the Phase 3 GLOW and Phase 2 CAPTIVATE trials, which indicated clinically meaningful improvements in progression-free survival and overall survival at a 64-month follow-up.
- Market Impact: This authorization extends to all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive ABBV's sales growth in the European market and further solidify its leadership position in blood cancer treatment.
See More
European Commission Approves Expanded Indication for VENCLYXTO
- Indication Expansion: The European Commission has approved the use of VENCLYXTO in combination with acalabrutinib (with or without obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), significantly broadening its application in first-line treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib was shown to be superior to chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, thus providing patients with a more effective treatment option.
- Patient Benefits: The introduction of these new combination regimens not only offers chemotherapy-free fixed-duration options but also has the potential for treatment-free intervals, significantly improving patients' quality of life and reducing treatment burdens.
- Market Impact: This approval allows VENCLYXTO to be available across all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive AbbVie's sales growth in the European market and further solidify its leadership in the blood cancer treatment sector.
See More
AbbVie Expands VENCLYXTO Indication for CLL Treatment
- Indication Expansion: The European Commission has authorized the use of VENCLYXTO in combination with acalabrutinib (with optional obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), further solidifying AbbVie's leadership in hematologic cancer treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib demonstrated superior efficacy over chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, providing patients with a more effective treatment option.
- Patient Benefits: The new therapy's fixed-duration and chemotherapy-free nature offers the potential for treatment-free intervals, significantly improving patients' quality of life and meeting the evolving needs of patients and healthcare providers for flexible treatment options.
- Market Potential: With VENCLYXTO approved in over 80 countries, AbbVie enhances its competitive edge in the global market through this indication expansion, which is expected to drive future revenue growth for the company.
See More
Analysis of High-Yield Dividend ETF Investments
- Overview of High-Yield ETFs: The Vanguard High Dividend Yield ETF (VYM) includes 608 stocks with a current dividend yield of 2.24%, and while it has underperformed the S&P 500 over the past five years, it has outperformed it in 2026, indicating its potential for providing steady income during volatile periods.
- Portfolio Diversification: VYM's largest sector is financials (20.2%), followed by technology (14.8%) and industrials (14.2%), allowing investors to diversify risks across different economic sectors and reduce reliance on a single industry.
- Schwab Dividend ETF Performance: The Schwab U.S. Dividend Equity ETF (SCHD) holds 103 stocks with a dividend yield of 3.29%, and although its long-term performance has lagged behind VYM and the S&P 500, it has shown strong performance in 2026 with a year-to-date total return of about 17.8%.
- Considerations for ETF Selection: When choosing between VYM and SCHD, investors should consider diversification and safety, as VYM offers greater diversification with 608 stocks, while SCHD is more attractive in terms of dividend yield, making it suitable for those seeking stable income.
See More
